Charles River Laboratories has opened a new preclinical development facility in Shanghai, China which, the firm says, will act as a centre of excellence and help strengthen its position in the global outsourcing market.
Charles River Laboratories has agreed to buy US-based drug discovery imaging expert Molecular Imaging Research, Inc. (MIR) for approximately $12.5m (€8.8m) in cash.
Charles River Laboratories saw its operating income advance 16 per cent to $77m in the second quarter on strong demand for its research services division, and also announced a $53m deal to buy a German contract service organisation.
Charles River Laboratories' portable endotoxin testing system, the
Endosafe PTS, has been successfully used to detect bacteria on the
International Space Station (ISS).
Contract research organisation (CRO) Charles River Laboratories has
announced it will establish a presence in China by signing a joint
venture deal with Shanghai BioExplorer, a Chinese preclinical
services provider.
Charles River Laboratories confirmed it is persevering in its
intention to focus on its preclinical and Phase I businesses while
abandoning its late stage development services, during a conference
earlier this month.
Kendle has seized a chance to expand and diversify its business,
snapping up the Phase II-IV Clinical Services unit of Charles River
Laboratories after it decided to get out of this area of clinical
trial services and focus instead...
Charles River Laboratories saw a double-digit boost in fiscal first
quarter revenues reflecting a jump in operating earnings, helped by
its acquisition of Inveresk Research Group and the emerging trend
in outsourcing preclinical services.